Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.

Understanding the Biology of Colorectal Cancer
William Grady

Chemoprevention of Colorectal Cancer
Paul Engstrom

Screening and Surveillance
Arnold Markowitz

First Line Cytotoxic Chemotherapy Options
Ed Chu

Angiogenesis Inhibitors in Colorectal Cancer
Charles Blanke

EGFR Inhibitors in Colorectal Cancer
Paulo Hoff

Salvage Chemotherapy Strategies in Metastatic Disease
Heinz-Joseph Lenz

Adjuvant Chemotherapy of Stage II and III Colon Cancer
Richard Goldberg

Management of Locally Advanced Rectal Cancer
David Cunningham

Chemotherapy Issues with Resectable Metastases of Colorectal Cancer
Axel Grothey

Percutaneous Ablative Therapies for Colorectal Cancer
Karen Brown

Diagnostic Imaging Modalities in Metastatic Colorectal Cancer
Larry Schwartz

Nursing Issues in Colorectal Cancer Chemotherapy
Ellen Hollywood and Deborah Semple

Pain Management in Colorectal Cancer
Vivek Tim Malhotra

Future Prospects for New Agents and Strategies in Colorectal Cancer
Chris Takimoto